COVID-19 incidence did not increase with corticosteroid injections – Consumer Health News

WEDNESDAY, July 13, 2022 (HealthDay News) — Adults who received image-guided corticosteroid injections for musculoskeletal pain between April 2020 and February 2021 had a lower incidence of symptomatic COVID-19 than the general population of Massachusetts, according to a study published online July 5 in Radiology.

Joao RT Vicentini, MD, of Massachusetts General Hospital in Boston, and colleagues examined the incidence of symptomatic COVID-19 in people receiving image-guided corticosteroid injections for musculoskeletal pain between April 2020 and February 2021 in a prospective multicenter cohort study. A total of 2,190 adult participants underwent 2,714 corticosteroid injections; follow-up data was available for 1960 adults who received 2484 injections. The Massachusetts COVID-19 Response Reporting website was used to obtain the incidence of COVID-19 in the state during the same period.

Researchers found that 0.5 and 2.2 percent of participants had COVID-19 within 28 days of corticosteroid injection and up to four months after injection, respectively. This was lower than the incidence rate of COVID-19 in the general population, which was 7.5% in the population of Massachusetts during the same period. Compared to the entire cohort who received corticosteroid injections, participants with COVID-19 at 28 days had an elevated body mass index.

“These findings provide reassurance to providers and individuals who rely on corticosteroid injections for the management of musculoskeletal pain during potential new outbreaks of COVID-19, even in settings with low vaccination rates,” the authors write. .

Summary/Full text